SS-31 (Elamipretide) vs Teriparatide
A side-by-side research comparison of SS-31 (Elamipretide) and Teriparatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | SS-31 (Elamipretide) | Teriparatide |
|---|---|---|
| Full name | SS-31 / Elamipretide (Bendavia) | Teriparatide (PTH 1-34) |
| Category | Anti-Aging | Anti-Aging |
| Status | Investigational | FDA-approved drug (prescription) |
| Mechanism | Targets cardiolipin in inner mitochondrial membrane, stabilizes cytochrome c binding, optimizes electron transfer efficiency, and reduces mitochondrial ROS by 50%. | Intermittent dosing of PTH 1-34 preferentially stimulates osteoblasts (bone-building cells) over osteoclasts, increasing bone formation, trabecular bone mass, and bone strength. |
| Molecular weight | 640.8 Da | 4117.8 Da |
| Half-life | 4-6 hours | ~1 hour (subcutaneous) |
| Bioavailability | High (SubQ) | ~95% subcutaneous |
| Typical dose | 5-40 mg | 20 mcg once daily (medical) |
| Frequency | Daily | Once daily |
| Route | Subcutaneous or IV | Subcutaneous injection |
SS-31 (Elamipretide) reported benefits
- Mitochondrial function optimization
- Reduced oxidative stress
- Cardioprotection
- Improved exercise capacity
- Renal protection
- Cellular energy
Teriparatide reported benefits
- Actively builds new bone
- Increases bone mineral density
- Reduces fracture risk (medical)
- Supports bone healing
Related comparisons
Research and educational reference only. Not medical advice.